Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)

Last updated: March 24, 2026
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Leukemia

Lymphoma

Treatment

N/A

Clinical Study ID

NCT05237245
APHP180684
2020-A02320-39
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of HTLV-1 chronically infected patients with / without extra-haematological disorders (cohort 2).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years old or older

  • HTLV-1 infected

  • T lymphoproliferation induced by HTLV-1 (cohort 1)

  • without T lymphoproliferation induced by HTLV-1 (cohort 2)

  • informed and accepted the collection of data

Exclusion Criteria

  • Patients refusal of participation

Study Design

Total Participants: 69
Study Start date:
March 23, 2022
Estimated Completion Date:
March 31, 2027

Connect with a study center

  • Hôpital Necker Enfants Malades

    Paris, 75015
    France

    Site Not Available

  • Hôpital Necker Enfants Malades

    Paris 2988507, 75015
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.